Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Rasche

Showing results (111-120 of 170) with videos related to

Pageof 17
Sort By:
Haematologica|April 4, 2024
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myelomaUmair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, et al.
Communications Biology|June 26, 2021
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemiaAndoni Garitano-Trojaola, Ana Sancho, Ralph Götz, et al.
Hemasphere|June 9, 2026
Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myelomaGala Vega, Daniel Morillo, Christine Riedhammer, et al.
Blood|April 23, 2017
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myelomaLeo Rasche, Edgardo Angtuaco, James E McDonald, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 22, 2023
CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell TumorsIngo Hartlapp, Philipp E Hartrampf, Sebastian E Serfling, et al.
Leukemia|April 15, 2018
Kinase domain activation through gene rearrangement in multiple myelomaGareth J Morgan, Jie He, Ruslana Tytarenko, et al.
British Journal of Haematology|October 11, 2014
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk diseaseKlaus M Kortüm, Christian Langer, Jorge Monge, et al.
Haematologica|February 2, 2023
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complexXiang Zhou, Andrej Besse, Jessica Peter, et al.
Cancer|July 9, 2025
Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 studyCarolina Schinke, Cyrille Touzeau, Albert Oriol, et al.
Blood|June 30, 2023
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysisAlexandra M Poos, Nina Prokoph, Moritz J Przybilla, et al.
Pageof 17

Showing results (111-120 of 170) with videos related to

Sort By:
Pageof 17
Haematologica|April 4, 2024
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myelomaUmair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, et al.
Communications Biology|June 26, 2021
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemiaAndoni Garitano-Trojaola, Ana Sancho, Ralph Götz, et al.
Hemasphere|June 9, 2026
Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myelomaGala Vega, Daniel Morillo, Christine Riedhammer, et al.
Blood|April 23, 2017
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myelomaLeo Rasche, Edgardo Angtuaco, James E McDonald, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 22, 2023
CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell TumorsIngo Hartlapp, Philipp E Hartrampf, Sebastian E Serfling, et al.
Leukemia|April 15, 2018
Kinase domain activation through gene rearrangement in multiple myelomaGareth J Morgan, Jie He, Ruslana Tytarenko, et al.
British Journal of Haematology|October 11, 2014
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk diseaseKlaus M Kortüm, Christian Langer, Jorge Monge, et al.
Haematologica|February 2, 2023
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complexXiang Zhou, Andrej Besse, Jessica Peter, et al.
Cancer|July 9, 2025
Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 studyCarolina Schinke, Cyrille Touzeau, Albert Oriol, et al.
Blood|June 30, 2023
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysisAlexandra M Poos, Nina Prokoph, Moritz J Przybilla, et al.
Pageof 17